Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.34 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201241 | 0.91 | PRMT6 (0.42) | CRHR1ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL16201350 | 0.87 | PRMT6 (0.41) | CRHR1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL16201374 | 0.85 | ALDH1A1 (0.48) | CRHR1ALDH1A1KDM4EGAA | |
| SCHEMBL16201405 | 0.84 | CRHR1 (0.47) | CRHR1ALDH1A1KDM4E | |
| SCHEMBL16201359 | 0.84 | CRHR1 (0.46) | CRHR1ALDH1A1KDM4EGAA | |
| SCHEMBL16201394 | 0.83 | CRHR1 (0.40) | CRHR1ALDH1A1KDM4E | |
| SCHEMBL16201414 | 0.80 | PRMT1 (0.41) | ALDH1A1KDM4ETDP1GAAPRMT3 | |
| SCHEMBL16201198 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAPRMT3CARM1 | |
| SCHEMBL16201387 | 0.78 | GAA (0.41) | CRHR1ALDH1A1KDM4EGAA | |
| SCHEMBL16125380 | 0.78 | CETP (0.38) | ALDH1A1KDM4EPRMT3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CRHR1 3768/4885ALDH1A1 686/4885KDM4E 157/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CRHR1 3785/4885ALDH1A1 895/4885KDM4E 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.